drugset
drugset / Trial / NCT02289209

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

NCT02289209 ↗

Phase 2 Completed 48 enrolled Dan Zandberg Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab, trade name Keytruda®).

Timeline

Start
2016-03-09
Primary completion
2023-08-31
Completion
2024-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma